- Home
- BIIB vs CPAY Comparison
BIIB vs CPAY Comparison
Compare BIIB & CPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CPAY
- Stock Information
- Founded
- BIIB 1978
- CPAY 1986
- Country
- BIIB United States
- CPAY United States
- Employees
- BIIB N/A
- CPAY N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CPAY EDP Services
- Sector
- BIIB Health Care
- CPAY Technology
- Exchange
- BIIB Nasdaq
- CPAY Nasdaq
- Market Cap
- BIIB 18.8B
- CPAY 24.6B
- IPO Year
- BIIB 1991
- CPAY 2010
- Fundamental
- Price
- BIIB $133.19
- CPAY $337.15
- Analyst Decision
- BIIB Buy
- CPAY Buy
- Analyst Count
- BIIB 27
- CPAY 14
- Target Price
- BIIB $188.17
- CPAY $397.17
- AVG Volume (30 Days)
- BIIB 1.3M
- CPAY 503.7K
- Earning Date
- BIIB 07-31-2025
- CPAY 08-06-2025
- Dividend Yield
- BIIB N/A
- CPAY N/A
- EPS Growth
- BIIB 26.39
- CPAY 6.08
- EPS
- BIIB 10.12
- CPAY 14.26
- Revenue
- BIIB $9,816,400,000.00
- CPAY $4,045,005,000.00
- Revenue This Year
- BIIB N/A
- CPAY $13.37
- Revenue Next Year
- BIIB N/A
- CPAY $10.56
- P/E Ratio
- BIIB $13.16
- CPAY $23.69
- Revenue Growth
- BIIB 1.59
- CPAY 6.68
- 52 Week Low
- BIIB $110.04
- CPAY $264.08
- 52 Week High
- BIIB $238.00
- CPAY $400.81
- Technical
- Relative Strength Index (RSI)
- BIIB 60.40
- CPAY 54.54
- Support Level
- BIIB $123.90
- CPAY $325.58
- Resistance Level
- BIIB $134.75
- CPAY $342.19
- Average True Range (ATR)
- BIIB 3.53
- CPAY 9.88
- MACD
- BIIB 0.04
- CPAY 0.95
- Stochastic Oscillator
- BIIB 86.48
- CPAY 62.98
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CPAY Corpay Inc.
Corpay Inc is a corporate payments company that helps businesses and consumers manage and pay their expenses. Its suite of modern payment solutions helps customers manage vehicle-related expenses, lodging expenses, and corporate payments. Its reportable segments are; Vehicle Payments, Corporate Payments, Lodging Payments, and Other. The group's geographic areas are the United States, Brazil, the United Kingdom, and Other.